Figure S1. Pharmacological characterization of HUVEC responses to COA-Cl. (A) Results of cAMP assay. HUVEC were treated for 30 min with forskolin (25 μmol/L) or W146 (10 μmol/L), followed by COA-Cl (100 μmol/L for 10 min), as indicated. They were then subjected to cAMP determination (n = 3). (B) Results of immunoblot (IB) analyses, in which HUVEC were treated with DMS (10 μmol/L for 30 min), an inhibitor of sphingosine kinase, followed by COA-Cl (100 μmol/L for 10 min). Cells were harvested and were subjected to IB using antibodies directed to phospho- and total-ERK1/2, as above (n = 3). (C) Results of receptor desensitization assay. Some cells had been pretreated (“Pre-Tx”) with COA-Cl (100 μmol/L), S1P (100 nmol/L), or vehicle for 60 min prior to COA-Cl (100 μmol/L for 10 min) (n = 3).

Figure S2. Comparison of COA-Cl actions with S1P in HUVEC. (A) Results of immunoblot assays using the cell lysates derived from HUVEC treated with S1P (1 μmol/L) or with COA-Cl (100 μmol/L) for the times indicated, performed in an identical culture batch. They were subjected to IB for phospho- and total-ERK1/2 as above. Blots were also reprobed with antibodies directed to phospho- and total-Akt, as well. The degrees of ERK1/2 phosphorylation were quantified and are summarized in a graph shown in the (B) (n = 4). (C and D) Results of tube formation assays, in which cells were treated with vehicle, VEGF (10 ng/mL), S1P (1 μmol/L), or COA-Cl (100 μmol/L), performed in the identical cellular preparations (n = 5).

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.